Journal of veterinary internal medicine · 2026
Plasma proteomic profiling in dogs with pheochromocytoma.
СтатьяМногоцентровое исследованиеObservational Study, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van den Berg Marit F, Rodríguez-Rojas Alexandro, Doulidis Pavlos G, Pisoni Luciano, Burgener Iwan A, Galac Sara
Аннотация
BACKGROUND: Pheochromocytomas (PCCs) in dogs are challenging to diagnose. Plasma proteomics offers a minimally invasive approach to identify circulating biomarkers and disease-relevant pathways.
HYPOTHESIS/OBJECTIVES: To compare the plasma proteome of dogs with PCC and controls to (1) identify differentially abundant proteins, (2) characterize altered pathways, and (3) nominate candidate circulating biomarkers and therapeutic targets.
ANIMALS: Plasma from 10 client-owned PCC dogs and 10 healthy controls.
METHODS: Multicenter, retrospective, observational, exploratory study using label-free liquid chromatography-mass spectrometry. Primary outcomes were the identification of differentially abundant proteins and characterization of altered pathways and protein functions.
RESULTS: Principal component analysis demonstrated clear separation between PCC and control dogs. Of 261 reliably quantified proteins, 51 were differentially abundant (false discovery rate-adjusted P < .05). Of these, 33 had a log2 fold change of >1 or < -1, with 15 showing higher and 18 lower plasma abundance in PCC. Compared with controls, PCC dogs showed increased abundance of proteins linked to cell adhesion/migration and metastatic potential, hemostasis, and regulation of apoptotic signaling, alongside alterations in oxidative stress and metabolic processes. Several proteins with higher abundance, including CD44, peroxiredoxin-2, and peptidyl-prolyl cis-trans isomerase, emerged as promising candidates for therapeutic exploration.
CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with PCC exhibit a distinct circulating protein signature vs healthy controls, providing clues to PCC pathogenesis and nominating proteins as diagnostic biomarker candidates and potential therapeutic targets.
HYPOTHESIS/OBJECTIVES: To compare the plasma proteome of dogs with PCC and controls to (1) identify differentially abundant proteins, (2) characterize altered pathways, and (3) nominate candidate circulating biomarkers and therapeutic targets.
ANIMALS: Plasma from 10 client-owned PCC dogs and 10 healthy controls.
METHODS: Multicenter, retrospective, observational, exploratory study using label-free liquid chromatography-mass spectrometry. Primary outcomes were the identification of differentially abundant proteins and characterization of altered pathways and protein functions.
RESULTS: Principal component analysis demonstrated clear separation between PCC and control dogs. Of 261 reliably quantified proteins, 51 were differentially abundant (false discovery rate-adjusted P < .05). Of these, 33 had a log2 fold change of >1 or < -1, with 15 showing higher and 18 lower plasma abundance in PCC. Compared with controls, PCC dogs showed increased abundance of proteins linked to cell adhesion/migration and metastatic potential, hemostasis, and regulation of apoptotic signaling, alongside alterations in oxidative stress and metabolic processes. Several proteins with higher abundance, including CD44, peroxiredoxin-2, and peptidyl-prolyl cis-trans isomerase, emerged as promising candidates for therapeutic exploration.
CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with PCC exhibit a distinct circulating protein signature vs healthy controls, providing clues to PCC pathogenesis and nominating proteins as diagnostic biomarker candidates and potential therapeutic targets.